基于抗原的免疫调节疗法治疗1型糖尿病:精准医学时代
本文综述了基于抗原的免疫调节疗法在1型糖尿病精准医学中的应用。研究显示,向1型糖尿病高危或患者给予胰岛自身抗原及其肽段具有可行性、安全性和耐受性,机制研究提示胰岛自身免疫向有利方向改变并出现免疫调节迹象。但剂量、给药频率、给药途径和佐剂使用等重大挑战仍存,需未来研究指导免疫耐受诱导。
要点
- 基于抗原的免疫疗法在1型糖尿病中显示可行性、安全性和耐受性
- 机制研究提示胰岛自身免疫改善并出现免疫调节迹象
- 剂量、给药频率、途径和佐剂使用仍是主要挑战
核心结论
- 基于抗原的免疫调节疗法在1型糖尿病中可行、安全且耐受性良好,并显示免疫调节迹象,但尚未解决剂量、给药途径等关键问题。
研究设计与样本
- 本文为综述,基于基础科学发现和新兴试验数据,探讨基于抗原的免疫疗法在1型糖尿病精准医学中的应用。
主要发现
- 向1型糖尿病高危或患者给予胰岛自身抗原及其肽段具有可行性、安全性和耐受性。
- 机制研究提示胰岛自身免疫向有利方向改变,并出现免疫调节迹象。
关键数值与推荐
- 原文未报告具体剂量、阈值或推荐条款。
临床怎么用
- 基于抗原的免疫疗法可能为1型糖尿病的组织特异性预防提供机会,但需进一步研究确定剂量、给药频率、途径和佐剂。
局限性
- 剂量和给药频率、给药途径以及佐剂使用等重大挑战仍未解决。
- 目前尚无针对1型糖尿病的抗原免疫疗法获批。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Precision medicine has emerged as a mantra for therapeutic approaches to complex diseases. The defining concept relies on a detailed insight into disease pathogenesis and therapeutic mechanism. Although the type 1 diabetes field has gained new insights into disease endotypes and indications of efficacy for several therapies, none of these is yet licensed, partly because of immune suppressive side-effects beyond control of islet autoimmunity. New strategies designed to regulate the immune system continue to emerge as basic science discoveries are made, including the use of antigen-based immunotherapies. A single agent or approach seems unlikely to halt disease progression in all people with or at risk of type 1 diabetes; as such, tailored methods relying on patient subgroups and knowledge of disease endotypes are gaining attention. Recent insights into disease mechanisms and emerging trial data are being translated into opportunities for tissue-specific prevention of progressive loss of β-cell function and survival. Results so far point to feasibility, safety, and tolerability of administration of islet autoantigens and peptides thereof into recipients with or at risk of type 1 diabetes. Findings from mechanistic studies suggest favourable changes in islet autoimmunity, with signs of immune regulation. Major challenges remain, including those related to dose and dosing frequency, route of administration, and use of adjuvants. However, the first steps towards tissue-specific and personalised medicine in type 1 diabetes have been made, which will guide future studies into induction of immune tolerance to intervene in the initiation and progression of islet autoimmunity and disease.
引用
- Roep BO, Wheeler DCS, Peakman M, et al. Antigen-based immune modulation therapy for type 1 diabetes: the era of precision medicine. Lancet Diabetes Endocrinol. 2018. PMID: 30528100. doi:10.1016/S2213-8587(18)30109-8
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。